Candriam SCA’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Candriam SCA’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-194,693	Closed	-$134K	–	836
2020 Q4	$134K	Hold	194,693	–	–	﹤0.01%	781
2020 Q3	$438K	Hold	194,693	–	–	﹤0.01%	720
2020 Q2	$697K	Sell	194,693 -49,925	-20%	-$180K	0.01%	663
2020 Q1	$720K	Hold	244,618	–	–	0.01%	683
2019 Q4	$736K	Buy	+244,618	New	+$636K	0.01%	700

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Candriam SCA's BMY.RT Position: Q1 2021 in Review

Candriam SCA sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 194,693 shares — an estimated $134K sold.

Candriam SCA first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $736K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Candriam SCA reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Candriam SCA sold 194,693 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $134K.
Candriam SCA first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Candriam SCA's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $736K in Q4 2019.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Candriam SCA's 13F filing for Q1 2021, filed 29 Apr 2021.